Real-world Strangvac data shows nearly 100% protection
Cision•03/11/2026•02:30 ET
2
Key Highlights
- ➤100,000 Strangvac doses sold across the EU and UK
- ➤Only 3 confirmed S. equi infections followed primary vaccination
- ➤Confirmed infection incidence calculated at 0,006%
- ➤UK recorded one diagnosis among 920 cases after two primary doses
Expert Statements
Andrew Waller, CSO of Intervacc
“Around 3% of horses in the UK are vaccinated currently against strangles, often in response to outbreaks of disease where the risk of infection is high,”
Andrew Waller, CSO of Intervacc
“However, in the past two years only one of 920 diagnoses of strangles in the UK occurred in a horse that had received the two primary vaccination doses of Strangvac.”
Carl-Johan Dalsgaard, CEO of Intervacc
“The nearly 100% protection demonstrated in the real-world data set shows the strength of the vaccine and that prophylaxis is effective”
Carl-Johan Dalsgaard, CEO of Intervacc
“It also validates our platform where the precision in selecting the crucial antigens for infection is key to the performance of the vaccines.”
Intervacc Intervacc AB (publ) today announces that after the first 100.000 doses of Strangvac were sold in the EU and UK, only 3 cases of confirmed S. equi infection were reported in horses that completed their primary vaccination.
Strangles, a potentially lethal infection caused by Streptococcus equi, is the most frequently diagnosed infectious disease of horses worldwide. The bacteria are highly contagious, and infection is spread via direct, or indirect contact with infected horses or contaminated food, water or equipment.
Get started
Create a free account to read the full story.